B3Trade
A version of the BIOSECURE Act passes, aimed at some Chinese biotech suppliers
After failing in 2024, a reworked BIOSECURE Act was included in the US defence bill for 2026. It limits federal money for firms using certain "biotechnology companies of concern".
Dateline
Wuxi, Jiangsu
United States Capitol, Washington Photo: Martin Falbisoner, CC BY-SA 3.0, via Wikimedia Commons (cropped)
In one lineDrug makers are told to plan for fewer Chinese contract suppliers on US-funded work.
What passed
A version of the BIOSECURE Act was included in the US National Defense Authorization Act for fiscal year 2026, signed in December 2025. The 2024 version, which named several Chinese companies, did not pass.
What it does
The law restricts US federal agencies from buying from, or funding work with, "biotechnology companies of concern". Unlike the earlier draft, the final text relies on lists and processes run by the government rather than naming firms in the bill.
Why peptide makers watch it
Chinese contract makers produce a large share of peptide intermediates and some ingredient for Western drug companies. WuXi AppTec, based in Wuxi, built large peptide capacity in recent years. Companies on any final list would face limits on federally connected business.
Timing
Earlier drafts gave existing contracts years to wind down. Firms are expected to start qualifying second suppliers now.
The caveat
This summary is hedged: check the enacted text and any list published under it.
What it changes for supply
Chinese CDMOs make peptide ingredient and intermediates for many Western firms. A phased restriction pushes buyers toward suppliers elsewhere.
Still open
Which companies end up on the list, and how long existing contracts may run.
SourceNational Defense Authorization Act for fiscal year 2026; congressional summaries
Peptide Global covers how medicines are made and traded. Nothing here is medical advice.
